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Abstract 
Background: In patients with relapsed osteosarcoma, the surgical excision of all metastases, defined as second com-
plete remission (CR-2), is the factor that mainly influences post-relapse survival (PRS). Currently a validated follow-up 
policy for osteosarcoma is not available, both chest X-ray and computed tomography (CT) are suggested for lung sur-
veillance. The purpose of this study is to evaluate whether the type of imaging technique used for chest surveillance, 
chest X-ray or CT, influenced the rate of CR-2 and prognosis in patients with recurrent osteosarcoma.
Methods: Patients up to 40 years with extremity osteosarcoma enrolled in consecutive clinical trials and treated at 
the Rizzoli Institute from 1986 to 2009 were identified. Only patients who had lung metastases alone as first pattern of 
recurrence were considered for the analysis. The rate of CR-2, overall survival (OS) and PRS were the end-points of the 
study.
Results: The median follow-up was 47 months (1–300), 215 patients were eligible. Lung metastases were detected 
by chest X-ray in 100 (47%) patients, by CT in 112 (52%) and by symptoms in 3 (1%). CR-2 rate was 60% for patients fol-
lowed by X-rays and 88% for those followed by CT (p < .0001). 5-year PRS was 30% (95% CI 21–39) in the X-ray group 
and 49% (95% CI 39–59) in the CT group (p = .0004). 5-year OS was 35% (95% CI 26–44) in the X-ray group and 60% 
(95% CI 51–70) in the CT group (p = .004).
Conclusions: A follow-up strategy with chest CT leads to a higher rate of CR-2 and significantly improves PRS and OS 
in osteosarcoma, compared to chest X-ray.
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Background
High-grade osteosarcoma is the most frequent primary 
bone tumor, with a peak of incidence in the second dec-
ade of life [1, 2]. The addition of multi-agent chemother-
apy to surgery alone significantly improved survival rate, 
however, almost 40% of patients with localized disease 
relapse [3]. Recurrences usually occur within 3 years after 
the end of treatment, but late relapses, even after more 
than 10  years, are reported [4]. The most frequent site 
of metastasis is the lung (more than 80% of cases), local 
recurrences occur in less than 10% of cases [5–7].
Post-relapse survival (PRS) after distant recurrence 
is poor [5–7]. The complete removal of all metastases, 
defined as a second complete surgical remission (CR-2), 
is the main prognostic factor for PRS and relate to long 
survival [8–16].
Other prognostic factors related to a better PRS are the 
site of relapse (lung vs others), the number of lung nod-
ules (less than two) and a relapse free interval (RFI) of 
more than 2 years [5–7].
The role of chemotherapy in recurrent osteosarcoma is 
not yet well defined, but it has recently been emphasized 
in patients with a short relapse-free interval or in those 
who cannot achieve a complete surgical remission [3, 5, 6].
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Osteosarcoma surveillance programs should be able to 
detect recurrence when complete removal of all known 
tumor sites is still feasible. Currently, an evidence-based 
follow-up policy is not available. International guidelines 
stress the importance of an intensive follow-up program 
focusing on the chest and on the primary tumor site, 
particularly for the first 4–5 years [3, 17]. A radiological 
follow-up is recommended for the chest, with X-ray or 
CT scan. Chest CT scan is more sensitive and sensible 
than chest X-ray in detecting lung metastases, but is bur-
dened by higher radiation exposure and costs [18–20]. In 
clinical practice, follow-up programs vary in the different 
centers, both in terms of schedule and in terms of imag-
ing techniques in use [21]. Whether the type of follow-up 
influences prognosis in patients with osteosarcoma is still 
debated.
In order to evaluate if the technique of chest surveil-
lance (X-ray or CT) influence CR-2 rate and survival, 
we performed a retrospective cohort analysis of patients 
treated in a single Institution.
Patients and methods
Patients enrolled in clinical trials performed at the Riz-
zoli Institute between 1986 and 2006 were included in 
the analysis. Details of these studies have been published. 
IOR/OS-2 enrolled patients from 1986 to 1989 [22], IOR/
OS-3 from 1990 to 1993 [23], IOR/OS-4 from 1993 to 
1995 [24], Pilot ISG/OS from 1996 to 1997 [25], ISG/
SSG-1 from 1997 to 2000 [26] and ISG/OS-1 from 2001 
to 2006 [27].
Briefly, protocols included patients aged up to 40 years 
with localized high-grade osteosarcoma of the extrem-
ity. The strategy of treatment was based on delayed sur-
gery after primary chemotherapy. The neo-adjuvant 
schemes of treatment were mainly based on metho-
trexate, doxorubicin, cisplatin,  ±ifosfamide. From our 
database we selected for the analysis the patients who 
relapsed and between these, those who had lung metas-
tases alone at time of the first recurrence. Clinical charts 
were reviewed. Data collection was in accordance with 
the local ethical committee standards. A statement on 
consent to use the data for scientific purposes and publi-
cation was obtained from all patients. The imaging tech-
niques used for chest surveillance changed over the study 
period. From 1986 to 1995 [22–24] follow-up was per-
formed with chest X-ray, from 1996 to 2000 [25, 26] both 
chest X-ray and CT scan were used. Since 2001 patients 
were followed up only by CT [27]. When chest X-rays 
was used, follow-up schedule was every 2 months for the 
first 2 years, every 3 months the 3rd year, and then every 
6 months. A confirmatory CT scan of the chest was per-
formed in case of suspected nodules. Starting from 1996 
all patients who completed chemotherapy underwent 
CT of the chest, whereas those who were already fol-
lowed up by X-rays continued with the same technique. 
When chest CT was used, follow-up schedule was every 
3 months for the first 2 years, every 4 months in the 3rd 
and 4th year, and then every 6 months. All the patients 
were evaluated in a multidisciplinary team at the time of 
recurrence of the disease. The surgical approach foresaw 
lateral thoracotomy and manual palpation of the whole 
lung. In case of bilateral lesions, a contemporary surgery 
or two-staged surgery was performed. A wedge resec-
tion was performed when possible. Surgical staplers were 
used only in selected cases.
The rate of patients who achieved CR-2, overall survival 
(OS), and post relapse survival (PRS) were the end-points 
of the study. For each patient, date of the first surgical 
remission (CR-1), date of the first recurrence, pattern of 
recurrence, the imaging technique used for chest follow-
up (X-ray or CT), relapse-free interval (RFI), number and 
size of lung nodules, laterality, treatment at recurrence 
were collected. Relapse free interval (RFI) was calculated 
from the date of CR-1 to first relapse. Post relapse sur-
vival (PRS) was calculated from the date of first relapse to 
date of death or last follow-up. Overall survival (OS) was 
calculated from the date of CR-1 to date of death or last 
follow-up. Survival curves were compared by Kaplan and 
Meier. Chi square and t test were used for comparison 
between groups when appropriate.
Results
Over the study period, 300 patients who recurred with 
lung metastases were identified. Lung metastases were 
associated with other recurrences in 63 patients, incom-
plete data were found in 22 patients. The remaining 215 
patients were eligible for the analysis (Fig.  1). Median 
age at time of the first relapse was 15  years (range 
6–43 years), 130 (60%) patients were male and 85 (40%) 
female.
Median RFI was 25 months (3–136 mos). Overall, 178 
(83%) patients underwent surgery and 159 (74%) achieved 
a CR-2 status. All patients who did not reach CR-2 died. 
The 3- and 5-year PRS was 45% (95% CI 38–52) and 39% 
(95% CI 32–46) respectively, and the median PRS was 
22 months (range 2–280 mos). With a median follow-up 
of 47 months (1–300 mos), OS was 64% (95% CI 58–71) 
at 3 years and 47% (95% CI 40–54) at 5 years.
Lung metastases were detected by chest X-ray in 100 
(47%) patients, by CT scan in 112 (52%) and by symptoms 
in 3 (1%) patients. These last 3 patients, all followed-up 
by chest X-ray, were excluded from the analysis, none 
achieved a CR-2 and they all died of the disease.
Comparing the two groups of patients we observed 
no difference in terms of age, sex and site of the primary 
disease, while the rate of good responder patients was 
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higher in the X-ray group compared to the CT group 
(Table  1). At first recurrence, the number of lung nod-
ules did not differs among the two groups, while the 
incidence of bilateral lung metastases was higher and 
nodules were larger when lung relapses were detected by 
chest X-ray (Table 2). We observed a shorter median RFI 
and a higher rate of patients with a RFI of <2 years in the 
CT group.
At the time of recurrence, the use of chemotherapy 
was mainly based on high-dose ifosfamide. As reported 
in Table  3 the percentage of patients who received 
chemotherapy at recurrence did not differ in the chest-
X-ray group compared with the CT group (p = .5). Most 
patients treated with chemotherapy underwent surgery, 
24 in the X-ray group and 34 in the CT group. In both 
groups only 7 patients were treated preoperatively.
Patients were surgically treated in two Centers (Unit 
of General Surgery of the University of Modena and 
Unit of General Surgery of the Rizzoli Institute) by three 
surgeons B.A., M.R., C.S. All patients underwent lat-
eral thoracotomy and manual palpation of the lung. In 
order to evaluate the whole lung, no patient was treated 
with video-assisted thoracoscopic resection. Up to 
2000, bilateral wedge resection was performed in 22% 
of the patients, monolateral wedge resection in 57% of 
the patients, lobectomy with or without wedge resec-
tion in 21%. In the most recent years the percentage of 
monolateral wedge resection was 70%, bilateral wedge 
Fig. 1 Patients eligible for the analysis, method of lung metastases detection and rates of CR-2. pts patients, X-ray chest X-ray, CT chest computed 
tomography, CR-2 second complete surgical remission
Table 1 Patient and disease features according to imaging 
technique used for follow-up







 Range 6–43 6–42 .7
 Median 15 16
Sex
 F 42 (42%) 42 (38%) .5
 M 58 (58%) 70 (62%)
Site
 Femur 49 (49%) 56 (50%) .9
 Tibia 30 (30%) 32 (29%)
 Humerus 16 (16%) 19 (17%)
 Other 5 (5%) 5 (4%)
Histological response (90 pts) (94 pts) .02
 Good 62 (69%) 49 (52%)
 Poor 28 (31%) 45 (48%)
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resection was 15%, lobectomy with or without wedge 
resection 15%.
Patients underwent surgery and achieved a CR-2 more 
frequently in the CT group as compared to the X-ray 
group (Table 3). CR-2 rate was 60% in patients followed 
up by X-ray, whereas it was 88% in those followed up by 
CT scan (p < .0001). We observed that the rate of patients 
who underwent surgery without achieving a CR-2 was 
higher in the chest X-ray group compared with CT 
group, 18 and 6% respectively (p = .01).
From 1996 to 2000 both X-ray and CT were used for 
chest surveillance. Seventy-five patients were included in 
this period, 19 were followed up by CT and 56 by X-ray. 
A CR-2 was obtained in all the patients followed with CT 
and in the 57% of patients followed by X-ray (p = .001).
The difference in terms of CR-2 translated in a signifi-
cant difference in terms of PRS and OS between the two 
groups (Fig. 2). The 3- and 5- year PRS was 33% (95% CI 
33–42) and 30% (95% CI 21–39) in the chest X-ray group 
and 58% (95% CI 49–68) and 49% (95% CI 39–59) in the 
CT scan group (p =  .0004) (Table 3). Overall survival at 
3 years was 58% (95% CI 48–68) in the X-ray group and 
72% (95% CI 63–80) in the CT scan group, at 5-years it 
was 35% (95% CI 26–44) and 60% (95% CI 51–70) in the 
two groups, with a difference that was statistically signifi-
cant. (p = .004) (Table 4). 
Discussion
Results from our analysis show that the routinely use of 
chest CT scan, compared with X-ray, in the follow-up of 
osteosarcoma patients leads to a higher rate of second 
complete surgical remission (CR-2) and, consequently, 
to a significant benefit both in terms of PRS, and in 
terms of OS.
One of the main aim of oncology follow-up is early 
detection of recurrence, especially when effective strat-
egy of treatment can be offered. We restricted the study 
population on patients who had metastases confined to 
the lung to emphasize better the potential benefit related 
to early diagnosis with regard to the follow-up programs. 
It is well known that this group of patients has a better 
probability of survival compared to that reported for 
those with multiple metastatic sites.
Relapse free interval of less than 2 years usually relate 
with a worse prognosis [5–7]. In our series we observed 
a higher rate of patients with RFI <2 years but a signifi-
cantly better PRS and OS in the CT group compared 
with the X-ray group. The median RFI was shorter when 
patients were followed-up by CT, suggesting that the bet-
ter prognosis observed in this group was probably due to 
the early diagnosis of recurrence, which led patients to be 
treated with surgery with radical intent more frequently, 
with a higher rate of CR-2.
The higher rates of necrosis after neo-adjuvant chemo-
therapy reported in the X-ray group compared with the 
CT group were probably related with the use of intraar-
terial infusion of cisplatin in most patients up to 1995 
[22–24].
It is widely accepted that CT scan is superior to X-ray 
for the detection of lung nodules, but is under discus-
sion whether the routine use of CT for chest surveillance 
can influence prognosis in patients with osteosarcoma. 
Data available in literature mainly comes from retrospec-
tive studies and only one prospective randomized study, 
which included both soft tissue and bone sarcomas.
It is interesting to note that in one study on soft tissue 
sarcomas where chest X-ray was used for follow-up, in 
21 (37%) of 57 patients, lung metastases were detected 
Table 2 Pattern of lung relapse according to imaging tech-
nique used for follow-up








 Median (months) 28.4 22.3 .01
 <2 years (pts) 49 (49%) 72 (64%) .02
Laterality
 Monolateral 63 (63%) 88 (79%) .01
 Bilateral 37 (37%) 24 (21%)
n. nodules (162 pts) 84 pts 78 pts .4
 1 52 (62%) 47 (60%)
 2–5 23 (27%) 21 (27%)
 >5 9 (11%) 10 (13%)
Size (112 pts) (cm) 54 pts 58 pts .03
 <2 20 (37%) 37 (64%)
 2–5 26 (48%) 19 (33%)
 ≥5 8 (15%) 2 (3%)
Table 3 Treatment and  incidence of second complete sur-
gical remission (CR-2) according to  imaging technique 
used for follow-up
pts patients, X-ray chest X-ray, CT computed tomography, Chemo chemotherapy, 







 Yes 73 (73%) 105 (94%) <.0001
 No 27 (27%) 7 (6%)
1°line Chemo (89 pts) (104 pts) .5
 Yes 31 (35%) 41 (39%)
 No 58 (65%) 63 (61%)
CR-2 60 (60%) 99 (88%) <.0001
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when the patients had symptoms of lung involvement 
[28].
Similar results were reported in a more recent paper 
[29] where patients with high-grade primary bone or 
soft tissue sarcoma of the extremities followed-up by 
chest X-ray were included. Thirty-seven percent of the 90 
patients with bone sarcomas who developed pulmonary 
metastases were detected outside the follow-up program, 
13 were symptomatic. Overall, only nine (10%) patients 
survived after recurrence.
A retrospective analysis on a heterogeneous group of 
174 patients with low and high grade soft tissue sarcomas 
has been reported [30]. Most were followed-up by chest 
X-ray. Only in 9 of 22 patients who developed isolated 
and asymptomatic lung metastases surgical resection was 
feasible whereas for the remaining patients the extent of 
the pulmonary disease did not allow metastasectomy.
A study that compared CT and X-ray of the chest in 
soft tissue sarcomass did not find any difference of sur-
vival related to the modalty of follow-up for the whole 
study population [31]. Nevertheless, focusing on the 54 
patients who recurred with lung metastases, the 4-year 
survival rate after detection of pulmonary metastasis was 
0% in the chest X-ray cohort whereas it was 31.6% in the 
chest CT cohort (p < .05). Interestingly, as shown in our 
analysis, also in this study, unilateral lesions of smaller 
size were more frequently detected in CT group, leading 
to a higher rate of surgical complete remission.
The same group recently published results from a small 
retrospective study on high grade extremity osteosar-
comas, both localized and metastatic [32]. The imagin-
ing technique recommended for chest surveillance was 
X-ray, CT scan was planned at the end of the treatment, 
in case of suspicious finding or in case of lung metasta-
sis at diagnosis [32]. Twenty-two patients relapsed with 
lung metastases alone, 3 were detected by symptoms, 
10 by X-ray and 9 by CT. The rate of patients surgically 
treated with curative intent was higher in the X-ray group 
(9/10) compared to CT group (6/9), as was number of 
patients remain relapse free, 5 in the X-ray group and 2 
in the CT group. According to the authors, this difference 
is probably related to the higher baseline risk of relapse in 
patients followed with CT.
Only one randomized prospective trial on follow-up 
programs for patients with sarcoma of the extremities 
has been published [33]. Follow-up schedule (every 3 
and 6  months) and chest imaging (chest X-ray and CT 
scan) were compared in a two-by-two factorial design. 
Authors reported that 3-year overall survival was 67% in 
the CT scan group and 66% in the X-ray group and con-
cluded that the study demonstrated the non-inferiority 
of chest X-ray as compared to CT scan. Many criticisms 
can be addressed to this study. Firstly the heterogeneity 
of the sample, that included in the same analysis patients 
with soft tissue sarcomas and bone sarcomas, high and 
Fig. 2 Post relapse survival (PRS) and Overall survival (OS) at Kaplan and Meier analysis according to imaging technique used for follow-up. PRS post 
relapse survival, OS overall survival, X-ray chest X-ray, CT chest computed tomography
Table 4 Post relapse survival and  overall survival at  3 
and  5  years according to  imaging technique used for  fol-
low-up
pts patients, PRS post relapse survival, OS overall survival, CT computed 






 3-year PRS 33% (95% CI 33–42) 58% (95% CI 49–68)
 5-year PRS 30% (95% CI 21–39) 49% (95% CI 39–59)
OS
 3-year OS 58% (95% CI 48–68) 72% (95% CI 63–80)
 5-year OS 35% (95% CI 26–44) 60% (95% CI 51–70)
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low grade and primary and recurrent sarcomas. Fur-
thermore no data regarding histology of the bone sarco-
mas were given. It is well known that all these different 
entities have a different clinical behavior and a different 
response to treatments. For these reasons, the results 
obtained cannot be applicable to a single histotype and 
should not be considered conclusive. In our opinion, it is 
important to stress that the end point of the Indian study 
was the overall survival at 3 years. A rather short follow-
up period considering that the available lines of chemo-
therapy treatment and the aggressive surgical approach 
can prolong post relapse survival in bone and soft tissue 
sarcomas [3, 4, 34, 35]. Also in our study if we consid-
ered overall survival, the difference was less apparent at 
3 years (58 vs 72%), but at 5 years it reached a statistically 
significant (35 vs 60%).
We are aware of the radiation risks related to the rou-
tine use of CT for chest surveillance, particularly in 
children and young adults [36–39]. On the other hand, 
a 25% gain in terms of OS at 5 years as reported in our 
analysis indicated that the benefit related to the use of 
CT exceeded the risks of second malignancies associ-
ated [40].
A limit of our study is its retrospective design, and the 
long period of observation. A change in surgical tech-
niques over the years could be a potential bias influenc-
ing results. However surgical procedures that allow the 
removal of metastases including a small amount of nor-
mal tissue around, like wedge resections, were available 
since early 1980s. The vast majority of the patients in our 
study, including patients who relapsed in the 1980s, were 
treated with wedge resections, monolateral or bilateral. 
It is important that the surgeon could evaluate the whole 
lung, in order to detect unrecognized nodules, for this 
reason no patient was treated with thoracoscopic resec-
tion [41]. Moreover, in the group of patients included 
when both X-ray and CT were used for chest surveil-
lance, the higher rate of CR-2 related with the use of CT 
compared with X-ray was confirmed. The higher rate of 
patients who underwent surgery without achieving CR-2 
reported in the X-ray group did not seem due to the 
availability of different surgical techniques, but rather to 
the delay of the diagnosis of recurrence and the higher 
incidence of large and bilateral lung metastases observed 
in this group.
Surgery was the treatment of choice at the time of 
first recurrence, however some patients in our series 
were treated with chemotherapy. The rate of patient 
treated with first line chemotherapy did not differ 
among the two group of patients. On the other hands, 
it is questionable whether chemotherapy at the time of 
recurrence has an impact on post relapse survival. In 
a previous paper including patients evaluated in the 
present analysis, we could not observe any benefit from 
chemotherapy in patients surgically free of disease [6]. 
A strength of our study is that we included a large and 
homogenous series of patients, treated and followed-
up in a single Institution. All patients had high grade 
localized osteosarcoma at diagnosis and lung metas-
tases alone at first recurrence. The surgical directions 
did not changed over the study period. At the time of 
recurrence all the patients were evaluated in a multi-
disciplinary way together with the surgeon and, if indi-
cated, they were treated by the same surgical team. In 
the group of patients followed-up with X-ray, in case 
of pathological findings, a confirmatory CT was per-
formed. At the same way, in case of uncertain diagno-
sis when very small size nodules were detected in the 
CT group of patients, a new confirmatory CT was per-
formed after 1 or 2 months, in order to evaluate the 
nodule growth. In the management of small lung nod-
ules, when usually the resectability is not a problem, it 
is important to assess their behavior, in order to avoid 
overtreatment.
Conclusions
In conclusion, in patients with osteosarcoma of the 
extremity a follow-up strategy based on chest CT allows 
a higher rate of second complete remission and signifi-
cantly improves prognosis with a higher probability of 
post relapse and overall survival when compared to sur-
veillance based on chest X-ray.
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